DZ-002 is under clinical development by Da Zen Theranostics and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DZ-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DZ-002 is under development for the treatment of advanced solid tumors including pancreatic cancer, castration-resistant prostate cancer and lymphoma. It is administered through intravenous route.
Da Zen Theranostics overview
Da Zen Theranostics, Inc. is a US-based company that develops a product that improves the visibility of cancer cells during diagnostic imaging.
For a complete picture of DZ-002’s drug-specific PTSR and LoA scores, buy the report here.